Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q3 FY25 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Feb 5, 2025
Slide 1: Exchange filing cover letter for investor presentation
February 5, 2025 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai-400001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400051 Re: Investor Presentation Dear Sir, Please fi
Slide 2: Earnings Presentation: Q3 & 9M FY25
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q3 & 9M FY25 5th February, 2025 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q3 FY25: At a Glance
Q3 FY25: At a Glance Revenue from Highlights of Q3 FY25 R&D Operations ❑ Total revenues grew 17% YoY. ₹ 52,691 mn ₹ 5,031 mn ❑ India formulations business grew faster than the market led by strong 17% YoY 9.5% of revenues chronic outperformance (secondary sales gr of 8% as per IQVIA). ❑ Consumer Wel
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (₹ mn) Gross Profit (₹ mn) and Gross Margin % 67.4 % 70.9 % 74.4 % 71.9 % 69.9% 62,075 55,338 46,214 52,370 52,691 39,223 37,656 45,052 36,858 30,367 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Total R&D (₹ mn) and % to R
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (₹ mn) Organic Capex (₹ mn) 14,199 3,014 3,017 2,907 11,823 10,235 2,137 2,126 9,112 7,896 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Net Cash (₹ mn) Net Working Capital* (₹ mn) 71,427 65,354 62,596 30,916 60,585 56
Slide 7: India Formulations business
India Formulations business Strong chronic performance driving the overall outperformance Highlights for the quarter India Formulations Sales (₹ mn) Q3 FY25 Revenue ▪ Grew faster than the market with a secondary sales Contribution growth of 8% YoY. 14,273 14,569 14,982 13,806 13,758 Chronic segment
Slide 8: Consumer Wellness
Consumer Wellness Robust volume uptake amidst muted demand scenario in industry Highlights for the quarter Consumer Wellness Sales (₹ mn) Q3 FY25 Revenue Contribution ▪ Volume growth remained robust at 4.8% amidst 8,366 7,755 muted demand scenario. 4,875 4,488 ▪ Personal care segment witnessed stron
Slide 9: US Formulations business
US Formulations business Base business volume expansion and new launches led to strong growth Highlights for the quarter US Formulations Sales (₹ mn) Q3 FY25 Revenue Contribution ▪ Filed 10 ANDAs and received approval for 3 new 30,929 products. 25,235 24,168 24,096 18,427 ▪ Launched 5 new products.
Slide 10: International Markets Formulations business
International Markets Formulations business Strong growth on the back of resilient demand across markets Highlights for the quarter IM Formulations Sales (₹ mn) Q3 FY25 Revenue Contribution ▪ The business is emerging as a strong third growth 5,389 5,702 4,937 4,960 5,309 engine. ▪ Registered robust
Slide 11: Updates on Innovation (1/2)
Updates on Innovation (1/2) NCE: Saroglitazar Magnesium • Data monitoring and follow-up is going on post the completion of patient recruitment for Phase II(b)/ III clinical trials for PBC indication and Phase II(b) clinical trials for MASH indication for the US market. • Phase II(b)/ III trials data
Slide 12: Updates on Innovation (2/2)
Updates on Innovation (2/2) Biotech R&D • Completed Phase III clinical trials for one of the biosimilars. • Submitted an application to the DCGI seeking permission to initiate Phase III clinical trials for one of the biosimilar ADCs. • On the novel biologics front, received permission from RCGM to i
Slide 13: Zydus at a Glance
Zydus at a Glance ~$2.35 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 8 R&D Centers For NCE, APIs, Generics, Vaccines Biosimilars and Wellness products Among 1st Revenues from India Approved product for >35% In >55% of product Geography (Formulations Top 3 families mar
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q3 Q3 YoY Q2 QoQ 9M 9M YoY ₹ mn FY25 FY24 gr. % FY25 gr. % FY25 FY24 gr. % Total Income from Ops. 52,691 45,052 17.0% 52,370 0.6% 1,67,136 1,40,136 19.3% Gross Contribution (GC) 36,857 30,367 21.4% 37,656 -2.1% 1,20,727 93,969 28.5% Gross Margin % 69.9%
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q3 Q3 YoY 9M 9M YoY ₹ mn FY25 FY24 gr. % FY25 FY24 gr. % A. On operating transactions (above EBITDA line) -1,810 -228 -694.3% -2,000 -807 -148.0% a. Included in COGS 17 -22 176% 28 -50 156.4% b. Part of other operating expenses (shown separately) -1,826 -206 -78
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C